FIXX News and Press, Homology Medicines Inc. From 11/05/20

Homology Webcast / Conference Call Scheduled for Friday, November 6 at 4:30 p.m. ET BEDFORD, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the upcoming oral presentation of data from the dose-escala...

SAN FRANCISCO , CA / ACCESSWIRE / October 23, 2020 / Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided. FULT Investo...

Homology Medicines ([[FIXX]] +3.5%) has announced a new in vivo gene therapy development program for the treatment of mucopolysaccharidosis type II (MPS II), or Hunter syndrome.Development candidate HMI-203 is a potential one-time AAVHSC treatment designed to deliver functional copi...

HMI-203 Leverages Ability to Cross Blood-Brain-Barrier Following I.V. Administration, and Preclinical Data Show ed Improvements in Key Disease Biomarkers Program Expands Homology’s CNS P...

BEDFORD, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following virtual conferences: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit o Fireside Chat: S...

BioMarin ( BMRN ) received a complete response letter or CRL for their hemophilia A gene therapy Valrox last week. As a result, the earliest commercial launch is now in 2023. Audentes ( ALPMF ) provided an update on their please 3 neuromuscular ASPIRO clinical trial indicating a third pati...

Genomic medicine, the next major biotech era, is primarily pre-commercial though a few medicines have been approved. The list of FDA-approved cellular and gene therapy products did increase in July when the second Kite Pharma ( GILD ) cell therapy - Tecartus - was approved for relapsed/refract...

Homology Medicines (NASDAQ: FIXX ) : Q2 GAAP EPS of -$0.78 misses by $0.02 . More news on: Homology Medicines, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Three Cohorts Enrolled in Phase 1/2 pheNIX Gene Therapy Trial for PKU Progressed Into Later Stages of IND-Enabling Studies for MLD Gene Therapy and PKU Gene Editing Programs and Published Key Data Successfully Executed Multiple Internal 2,000-Liter Bioreactor Runs Using Comme...

- Executive with Extensive Rare Disease Expertise in Global Finance and  Commercial Operations - BEDFORD, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Jeff Poulton has been appointed to the Boar...